Scientific deep-dive
NAD+ Injections: What the Evidence Shows
A 2026 systematic review screened 113 studies and found no outcomes trials of injected NAD+ for anti-aging or wellness. With sermorelin, it is one of the two most common add-ons in our register: 142 of 560 sellers offered NAD+ and 147 offered sermorelin at the August 2026 count.
NAD+ and sermorelin are the two things most often sold beside a GLP-1, often under the heading of peptide therapy, although NAD+ is not a peptide. In our own register at its August 2026 count, 142 of 560 sellers listed NAD+ and 147 listed sermorelin, and NAD+ is nearly always sold as an injection or a drip. A systematic review published in 2026 screened the entire literature and found no outcomes trials of injected NAD+ at all for the purposes it is sold for.[1] The evidence people cite is real, but it is about a different product.
Oral precursors and injected NAD+ are not the same question
Almost every human trial in this field tests an oral precursor, nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), taken as a capsule.[4] What clinics sell is NAD+ itself, pushed into a vein or a muscle. Those are different molecules by a different route, and the trial record does not carry across from one to the other. The two are compared directly in NAD+ vs NMN.
The 2026 review is unusually explicit about it. Working to PRISMA methodology across studies published between January 2010 and October 2025, the authors identified 113 eligible studies: 33 human intervention studies, 28 of them randomized, and 80 in rodents. On the injected form, not one eligible outcomes trial tested NAD+ itself, given intravenously or intramuscularly, for an anti-aging or wellness indication.[1]
One nonrandomized intravenous NMN study met inclusion criteria and primarily contributed short-term safety and biomarker information. An intravenous NAD+ pharmacokinetic pilot lacking eligible clinical outcomes was identified as contextual evidence only.— Gallagher and Emmanuel, Ageing Research Reviews, 2026
What the oral evidence found
Here the picture splits cleanly in two.
- Target engagement: consistent. Oral NR and NMN reliably raise NAD-related metabolites in blood and in cells, and were generally well tolerated over weeks to months.[1] The supplement does the biochemical thing it claims to do.
- Outcomes: heterogeneous, and often null. Effects on functional, metabolic, vascular and other healthspan-relevant endpoints were inconsistent and frequently absent or specific to a single endpoint.[1]
The gap between those two findings is the story of this field. Raising a molecule in the blood is not the same as changing how someone feels or functions, and NAD+ has become a case study in the difference. A 2025 review in Nature Metabolism covers the same terrain from the precursor side, setting out the clinical evidence alongside the methodological problems that make it hard to read.[2]
There are real positives in the record and they deserve naming. A 2021 randomized trial published in Science found that, in women with prediabetes, NMN improved insulin sensitivity in muscle.[3] That is a specific finding, in a specific population, on a specific endpoint, and it should be described that way, not the way it is usually sold. The full trial-by-trial record on aging markers is in NAD+ and longevity: what the trials show.
What this looks like on a seller's site
NAD+ occupies a particular slot in the telehealth catalog. It is rarely the thing you arrived for; it appears once you are already buying something else, usually framed around energy, focus, recovery or aging. Of the 142 sellers in our register that offer it, only ten publish what it costs.
A published price is the easiest disclosure a seller can make, and the overwhelming majority of these sellers do not make it for this product. Clover Meds is an exception: its NAD+ page lists $198 for a 4-week supply of twelve 80 mg subcutaneous injections. IonicMD prints its price as well, $199 per 4 weeks for a twice-weekly NAD+ injection. Stone Health charges $229 every 4 weeks and offers NAD+ as an injection, a nasal spray or a tablet at that one price. Sculpt Rx is more typical, selling NAD+ injections beside its GLP-1s with no price on the site.The same pattern holds for glutathione, the third most common add-on, which only a handful of sellers price. Our seller comparison shows what each one discloses, and what cannot legally be compounded covers the harder regulatory line that some peptide menus cross. Another metabolic add-on sold online, 5-amino-1MQ, rests on mouse studies alone. L-carnitine shots borrow their case from oral supplement trials.
Look at a few catalogs and the slot is easy to spot. Mondae sells NAD+ injections beside its compounded GLP-1s, along with sermorelin and glutathione, and LifespanningRx folds NAD+ into a wider peptide and longevity program that has a weight-loss arm. Rebody Health has gone further: it no longer sells GLP-1 medication at all, and NAD+ is one of the prescription peptides it now sells, in forms that include a spray and a cream. Ivim Health also lists NAD+ and sermorelin next to its compounded semaglutide and tirzepatide.
Elsewhere it is a side line. Glam Health offers NAD+ wellness plans next to its GLP-1 cards. MangoRx, Sunlight and Obu Health each list NAD+ beside a GLP-1, and so do YourEra, MadeMed and TelePeptide. Ora Medical Clinic lists NAD+ among its add-on treatments with metformin, sermorelin and vitamin B12, without prices. Limitless Male, an in-person men’s clinic chain, offers compounded NAD+ by injection and also publishes no price. At Restore Hyper Wellness, a franchise of studios, NAD+ is given in person as an IV drip or an intramuscular shot. If one of them offers it to you, ask for the cost in writing and what the prescriber expects it to do, because the trials above do not answer that for the injected form. Ironvale RX does not sell NAD+ on its own at all: it is a $100-a-month add-on to a GLP-1 bundle, paired with ondansetron if prescribed.
Where the evidence stands
NAD+ biology is a serious research field, not a fraud. The usual premise, that NAD+ falls with age, is less settled in people than sellers imply: a 2026 study across seven human cohorts found whole-blood NAD+ stable with age, which does not settle what happens inside tissues.[6] Augmenting it does measurable things, and rodent work has repeatedly shown improvements across metabolic, mitochondrial, inflammatory and functional measures.[1] Reviews of NAD across clinical conditions continue to find the safety picture broadly reassuring.[5]
What has not happened is the step from that to a demonstrated benefit in people, for the injected product, at the price a clinic charges. The 2026 review’s own conclusion is that clinical effectiveness for anti-aging or wellness outcomes remains inconclusive, and that larger randomized trials with longer follow-up are needed, “particularly for parenteral approaches.”[1] Those are the ones being sold. A separate 2026 narrative review of IV NAD+ called the evidence preliminary and not enough to support routine clinical or wellness use.[7]
Frequently Asked Questions
References
- 1.Gallagher C, Emmanuel OO. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence Ageing Research Reviews. 2026. PMID: 41655607.
- 2.Vinten KT, Trętowicz MM, Coskun E, et al. NAD(+) precursor supplementation in human ageing: clinical evidence and challenges Nature Metabolism. 2025. PMID: 41083806.
- 3.Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women Science. 2021. PMID: 33888596.
- 4.Freeberg KA, Udovich CC, Martens CR, et al. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions The Journals of Gerontology: Series A. 2023. PMID: 37068054.
- 5.Gindri IM, Ferrari G, Pinto LPS, et al. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review American Journal of Physiology: Endocrinology and Metabolism. 2024. PMID: 37971292.
- 6.Trętowicz MM, Scantlebery AML, Schomakers BV, et al. Human whole-blood NAD(+) levels do not vary with age or lifestyle interventions Nature Metabolism. 2026. PMID: 42135539.
- 7.Alangari A, Arif J, Al Qureshah F, Alkhodairy F. Narrative review of intravenous NAD(+) and NAD(+) precursors in wellness and translational medicine Frontiers in Aging. 2026. PMID: 42787547.
Compare the sellers
Rankings
Related research
The Peptide Menu: What Has Human Trials and What Does Not
In August 2026, 152 of the 560 sellers we tracked ran a peptide menu. We counted the human randomized trials behind each one. BPC-157: 226 papers, zero. The peptides with real evidence are the ones that became approved drugs.
8 min read
Retatrutide: What the Evidence Actually Shows
TRIUMPH-1 is now peer-reviewed: 25.0% at 80 weeks counting everyone randomized, against 28.3% in Lilly's release for the same trial. The drug is approved nowhere, and Lilly has not yet filed.
8 min read
CJC-1295 and Ipamorelin: What FDA Recorded
Sold as a stack for fat loss. FDA identified serious adverse events with CJC-1295 (increased heart rate and systemic vasodilatory reaction), and neither peptide has a weight-loss trial.
7 min read
Tesamorelin for Weight Loss? Read Its Own Label
Tesamorelin is FDA-approved, for reducing abdominal fat in HIV-associated lipodystrophy. Its label carries six words that matter: “Not indicated for weight loss management.”
6 min read
BPC-157 FDA Status: What the Agency Put on the Record
Not approved, and not on the list of substances a 503A compounding pharmacy may use. FDA recorded specific concerns: immunogenicity, peptide impurities, and “no, or only limited, safety-related information”.
8 min read
The Add-On Menu
At our August 2026 count, 152 of 560 sellers ran a peptide menu. Ranked by how often items appear, it is almost exactly the inverse of a ranking by evidence, and the reason is commercial rather than clinical.
5 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Wellorithm
Compounded semaglutide at a flat $247 every 28 days, any dose
From $247/mo
Get started →Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $179/mo
Get started →